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Key points 
We confirmed lesser receipt of specialist cardiologist care with older age in patients with 
NSTEMI. 
Cardiologist care resulted in receipt of more secondary prevention medication in all age 
groups, though with increased age less secondary prevention was given by both cardiologists 
and generalists.  
We found that increased co-morbidity could mostly explain the lesser use of secondary 
prevention medication in older patients by generalists.  
In those aged 85 and over, the benefit of being under a cardiologist was attenuated 
significantly when adjusted for receipt of secondary prevention medication particularly for 
shorter (30 day) outcomes. 
Any longer-term survival benefit associated with specialist cardiology care was attenuated 
with increased age itself. 
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Abstract 
Background 
Older patients are less likely to receive secondary prevention medicines following acute 
coronary syndrome (ACS). 
Objectives 
To examine the association of increasing age with receipt of specialist care and influence of 
specialist care on long-term mortality in patients with non-ST elevation myocardial infarction 
(NSTEMI) 
Design 
Cohort study  
Setting  
National ACS registry of England and Wales 
Subjects 
85,183 patients between 2006-2010 
Methods 
Logistic regression analyses to assess receipt of secondary prevention medicines (ACE 
inhibitor, b-blocker, statin, aspirin) by age group; multivariate Cox Regression models to 
examine longitudinal effect of cardiologist care on all-cause mortality by age group. 
Results 
Mean age 72.0 years (SD 13.0 years), mean follow up was 2.13 years. Older patients received 
less cardiologist care (70.2% of NSTEMI patients ≥85 compared to 94.7% of patients <65) 
and had more co-morbidity. Cardiologists prescribed more secondary prevention in all age 
groups than generalists but this was mostly explained away by co-morbidity (receipt of statin 
crude OR 1.51 (1.27,1.80), fully-adjusted OR 1.11 (0.92,1.33) in patients ≥85). Receiving 
cardiologist care compared to generalist care was associated with a decreased risk of death in 
all even after adjustment for co-morbidity, disease severity, secondary prevention; this 
benefit reduced incrementally with older age group (adjusted hazard ratio (HR) 0.58 
(0.49,0.68) aged <65; 0.87 (0.82,0.92) aged ≥85).  
Conclusion 
Older patients with NSTEMI were less likely to see a cardiologist, but reduced treatment by 
generalists was explained away by co-morbidity. Cardiologist care was associated with lower 
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mortality in all age groups than a generalist, but this survival benefit was less pronounced in 
older patients.  
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Introduction 
As the world ages,1 the typical cardiology patient in most developed world acute hospitals is 
an older adult with around a third of patients aged 75 or over.2 As risk of death after a cardiac 
event increases in older populations,3-4 the absolute benefit of treatment should increase as 
well, provided the risks of the treatment itself does not exceed the benefit it is designed to 
provide.5-6 However evidence from observational studies suggests that older patients are less 
likely to receive secondary prevention medicines following acute coronary syndrome 
(ACS).7-9 This is despite such treatments being indicated, and being shown to be effective 
within a clinical trial setting even in the very old,10-11 a risk-treatment paradox. Some have 
also previously suggested that older patients with coronary disease are less likely to receive 
care from a cardiologist.12-14  
Given older patients have a higher number of co-morbidities,15 and have a higher risk of 
complications (e.g., bleeding) after medical interventions for ACS,16 it is not known whether 
the observed deficiency in indicated care relative to younger patients is appropriate; less 
treatment may be explained by contra-indications to treatment. The representation in clinical 
trial populations of older patients is much lower than in real-world clinical practice and 
community study populations,2, 17 hence potentially rendering trial evidence on best practice 
in the older patient with ACS unrepresentative. Furthermore, a clinical trial that withheld 
secondary prevention medicines following ACS in older patients would be unethical. Large 
national clinical registries offer both representative study populations with high 
generalisability and statistical power and the appropriate study design to be able to analyse 
these questions.  
Using national registry data from patients with a NSTEMI (non-ST elevation myocardial 
infarction), we explored the hypothesis that co-morbidities and peri-admission complications 
would affect receipt of secondary prevention medication and this would confound the 
influence of cardiologist versus generalist care on receipt of treatments, by age group. Then, 
we sought to examine the association of cardiologist care on all-cause mortality over 
generalist care, and sought to adjust for both receipt of care but also co-morbidity and in-
hospital complications. 
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Methods 
Study design 
The Myocardial Ischaemia National Audit Project (MINAP) is a national registry which 
contains data from patients with an acute coronary syndrome admitted to all 230 National 
Health Service (NHS) hospital trusts in England and Wales, its methodology having 
previously been extensively described.18-21 MINAP has National Patient Information 
Advisory Group and Central Office for Research Ethics Committees approval for individual 
patient anonymous linkage for mortality. The current study obtained the ethical approval 
from the Faculty of Medicine & Health Sciences Research Ethics Committee, University of 
East Anglia. 
Study population 
We used records of admissions between 1st January 2006 and 31st December 2010 (the latest 
download available from MINAP at the time of our research grant award) for patients 
documented as having an ACS with a positive troponin blood test who were discharged alive. 
Data were cleaned by a statistician using a priori definitions and a data usage manual written 
jointly by clinical academics in cardiology and geriatric medicine (MJZ and PKM). We 
further validated variables using cross-checks with other data fields. The study sample 
consisted of 86,183 NSTEMI patients for the baseline table. The diagnosis of NSTEMI is 
made by the local clinician using their judgement of presenting symptoms and requiring 
elevated blood troponin concentration with or without electrocardiographic changes 
consistent with ischaemia. We did not seek to examine patients with STEMI (ST elevation 
myocardial infarction) due to its more clear management pathway regarding receipt of 
invasive coronary angiography (i.e., decision to perform primary coronary revascularisation 
in these patients is an instantaneous one made on the basis of the first ECG) - thus, the vast 
majority of these patients get specialist cardiologist input. As we have previously reported, 
the ratio of NSTEMI to STEMI increases significantly with age, with 74% of ACS in patients 
aged ≥85 being NSTEMI compared to only 44% in patients <65 years.9 We had data on 
receipt of cardiologist care for 72,216 of which 1,363 were missing data for Strategic Health 
Authority (SHA) leaving 70,853 patients for the final two tables. 
Study variables 
The MINAP registry dataset has pre-defined variables and we examined secondary 
prevention medicine therapy usage by using data on receipt of aspirin, ACE inhibitor or statin 
on discharge. MINAP has co-morbidity data limited to chronic kidney disease (CKD), 
congestive cardiac failure (CCF), peripheral vascular disease (PVD), cerebrovascular disease 
and chronic obstructive pulmonary disease (COPD) which were taken from past medical 
history. In-patient significant bleeding was defined as any bleed recorded by the clinician 
during the admission as well as retroperitoneal and intracranial haemorrhage. Other markers 
of disease severity conditions used in the prospective analyses were the in-hospital clinical 
events of re-infarction, cardiac arrest and having an abnormal electrocardiogram ((ECG), e.g. 
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ST or T wave changes or left bundle branch block). We used MINAP data on whether the 
patient had received cardiological care during the course of the admission and planned 
follow-up. Thus the assignment of a patient receiving cardiology versus generalist care was 
delineated using two points of data capture.  Cardiovascular risk factors used in the analyses 
were those available within MINAP - current smoking, known diabetes mellitus and known 
hypertension. All hospitals that input data into MINAP are capable of providing in-house 
specialist care for NSTEMI patients, though not all have on-site cardiac catheterisation 
facilities, data not available in MINAP. To account for potential regional differences in care, 
we used MINAP data on the patient's Strategic Health Authority, the regional body that 
oversees the provision of healthcare across a given region within the National Health Service 
of England and Wales. All patients in MINAP are followed up for their date of all-cause 
death through linkage to the National Health Service Central Registry using a unique number, 
and this was the outcome in the study.  
Statistical analysis 
We examined baseline patient characteristics, split by cardiologist and generalist care, in 
terms of age/sex, cardiovascular risk factors and co-morbidities. We then examined baseline 
data further to assess the association of cardiologist care on receipt of treatments compared to 
generalist care by age group via logistic regression analyses, and then adjusted for specific 
co-morbidities or peri-admission complications that might affect receipt of these treatments 
(receipt of ACE inhibitors adjusted for chronic kidney disease; receipt of aspirin adjusted for 
in-patient bleeding; receipt of beta-blockers adjusted for COPD). We then used a fully 
adjusted model to assess further the association between cardiologist care and receipt of 
treatments compared to generalist care. Odds ratios were adjusted for age as a continuous 
variable within each age group, sex and for receipt of these treatments on arrival (data 
available for all treatments except aspirin). 
To investigate the association of cardiologist care on time to death, we constructed Cox 
proportional hazards regression models adjusted for sex, then in turn for cardiovascular risk 
factors (diabetes, hypertension and smoking), co-morbidities (previous chronic kidney 
disease, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary 
disease and congestive cardiac failure), receipt of secondary prevention (ACE inhibitor, 
statin, aspirin, b-blocker) and case severity variables (re-infarction, bleeding, cardiac arrest 
and abnormal ECG) before using a full model to assess if these potential confounders 
affected the association between  cardiologist care and death, by age group. Outcomes were 
analysed at 30 days, 1 year and at censoring. 
All regression models (both crude and adjusted) included Hubert-White robust adjustment for 
intra-cluster correlation of outcomes within Strategic Health Authorities and all met the 
assumption of proportional hazards. 
Analyses were performed using Stata SE, version 11.0 (Stata, College Station, Texas). 
This work was supported by the Sir Halley Stewart Trust. 
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Results 
The mean age of the cohort was 72.0 years (SD 13.0 years), with 14,685 aged 85 or over. The 
mean follow-up was 2.13 years (SD 1.40). Less than 3% of patients (and less than 5% of 
patients aged 75-84) died in hospital. In the whole baseline cohort population, older patients 
received less cardiologist care (70.2% of NSTEMI patients ≥85 compared to 94.7% of 
patients <65). Patients’ baseline characteristics by age group and cardiologist/generalist care 
are shown in Table 1. The proportion of men reduced with older age group for both types of 
care, from 76.5% in patients <65 years old to 44.7% in patients ≥85 years old under a 
cardiologist. For both types of care, the proportion of smokers reduced with increasing age 
group, whereas both diabetes and hypertension demonstrated an inverted U-shaped 
relationship. Past history of chronic kidney disease, congestive cardiac failure and 
cerebrovascular disease rose with increasing age group. When compared side-by-side, those 
under generalist care had higher levels of co-morbidities across all pathologies and age 
groups. With older age, the risk of bleeding during the course of admission with NSTEMI 
increased. 
The association of cardiologist care on receipt of treatments and presence of co-morbidity 
compared to generalist care by age group is depicted in Table 2. Cardiologist care resulted in 
receipt of more secondary prevention in all age groups, though with increased age less 
secondary prevention was given by both cardiologists and generalists. We then sought to 
investigate for any confounding effect of specific co-morbidities or peri-admission 
complications on the association of cardiologist care and potentially contra-indicated 
prescribing on discharge (e.g. ACE inhibitor in CKD), by age group. There were only slight 
attenuations in the odds ratios of the receipt of these secondary prevention medications when 
these specific potential contra-indications to prescription were adjusted for (e.g. OR for 
receipt of ACE inhibitor from cardiologist care dropping from 1.44 to 1.38 in patients under 
65, from 1.50 to 1.38 in patients ≥85 years old, after adjusting for age, sex, ACE inhibitor on 
admission and chronic kidney disease). However in the full models, much of the reduced 
treatment in those under generalists was explained away. In patients under 65, the crude OR 
of 1.44 for receipt of ACE inhibitor comparing cardiologist to generalist care became non-
significant (1.07 (0.90, 1.27)) and this trend was observed across the age groups though just 
not becoming significant in the other groups. In the aspirin and statin groups, fully- adjusted 
models rendered all the ORs non-significant. For beta-blockers, the fully adjusted model 
attenuated the relationship, but cardiologists still tended to prescribe these more than 
generalists across all age groups.  
We then investigated the association of cardiologist care on time to death (table 3). In all age 
groups, receiving cardiologist care was associated with a decreased risk of death, but the 
benefit reduced incrementally with older age group (e.g. sex-adjusted hazard ratio (HR) 0.52 
(0.45,0.61) in patients aged <65, 0.78 (0.72,0.84) in patients aged ≥85). Adjusting for 
cardiovascular risk factors and case severity did not significantly alter the HRs for survival. 
When adjusting for co-morbidities, the HR attenuated in patients aged <65 where the HR rose 
from 0.52 to 0.62. Adjusting for receipt of secondary prevention led to minor changes of the 
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association in all age groups, but most marked in patients aged ≥85 where the HR rose from 
0.78 to 0.87. In the full model, there remained significant statistical differences between 
cardiologist care and generalist care on reduction in death rates in all age groups, though this 
benefit reduced incrementally with older age group (adjusted hazard ratio (HR) 0.58 
(0.49,0.68) aged <65; 0.87 (0.82,0.92) aged ≥85). When examining 30 day outcomes, receipt 
of secondary prevention fully explained away the survival difference between cardiologist 
care and generalist care in patients aged ≥85 (HR 1.06 (0.97,1.16),  table S1). 
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Discussion 
Using a national ACS registry cohort that reflects real-world clinical practice in England and 
Wales, we found older patients with NSTEMI received less cardiologist care, and that 
cardiologists prescribed more secondary prevention across all age groups compared to 
generalists. Adjustments for specific treatment contra-indications that might lead to both a 
cardiologist and generalist not prescribing a particular moderation were not able to explain 
this reduced receipt of secondary prevention medication observed in patients who did not 
receive cardiologist care but in the fully adjusted models, much of the reduced treatment in 
those under generalists was explained away. Any survival benefit associated with cardiology 
care was attenuated firstly with increased age, and then in older age groups by adjusting for 
receipt of secondary prevention, and in younger age groups by adjusting for co-morbidity. 
However, the long-term survival benefit associated with cardiology care was not explained 
away by receipt of more secondary prevention, though receipt of secondary prevention may 
equalise outcomes at 30 days.  
We have previously shown that older patients with NSTEMI receive less secondary 
prevention medication than younger patients;9 we add to those findings here by showing that 
the oldest patients are less likely to see a cardiologist (though a majority did still see one). 
Furthermore, older patients have more co-morbidity and in our fully-adjusted model with 
comprehensive adjustment we could explain away the reduced receipt of secondary 
prevention medication observed in all patients who did not receive cardiologist care, 
including both younger and older ones. This implies that the observed deficiency in indicated 
care in patients across the board by generalists  may be appropriate – younger patients under 
generalists must have a lot of co-morbidity to not come under cardiology care, whilst older 
patients with their higher co-morbidity on admission are more likely to be put under a 
generalist.  
In all age groups, receiving cardiologist care leads to better outcomes, but we demonstrated 
that the benefit of being under a cardiologist was attenuated significantly when adjusted for 
receipt of secondary prevention medication, particularly for shorter (30 day) outcomes. This 
illustrates that it is these treatments that make the biggest impact on survival in this age 
group, a group in which the failure to provide such treatments is potentially more likely to be 
associated with higher mortality than in younger groups (a risk-treatment paradox); this 
concept of relative survival has been previously described in this cohort.22 In our study these 
treatments do not fully close the gap in long-term survival between cardiologist and 
generalist care and it is likely that those were cared for by generalists are sicker, frailer and 
have more advanced disease; that may thus determine the long-term survival gap and 
overcome any benefit secondary prevention medication may have over a long follow-up 
period. Thus though cardiologist care was associated with lower mortality at all ages, this 
effect decreased with older age probably because it is harder to prevent death in older people 
even with specialist care. This finding is of particular relevance to the generalist, given the 
ratio of NSTEMI to STEMI increases significantly with age, and they may be increasingly 
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looked to for caring for these patients. More detailed phenotyping of the patient may have 
explained the long-term survival gap further. 
Considering the multiple needs of older patients, the care of the oldest patients under a 
generalist such as a geriatrician may be wholly appropriate but perhaps with a need for a 
systematic specialist care process to guide generalists on the usage of guideline-supported 
secondary prevention therapies, at least in the short-term. This may provide some support to 
increased use of medicines in the older patient, in whom polypharmacy is often of harm.23 
Thus we do not demonstrate here that care under a cardiologist should be mandated in the 
older patient with NSTEMI and in fact show that any under-treatment by generalists in the 
crude models is likely to be appropriate as they are mostly explained away by adjustments for 
co-morbidity. What we cannot say with any level of confidence from the current study is 
which older ACS patient should get specialist management - chronological age is not 
biological age and we cannot advocate an age cut-off for specialist care from our results.  
Furthermore, all-cause mortality, the only outcome available within MINAP, may not be as 
relevant an outcome to the older patient with ACS as future quality of life, symptom control, 
tolerance to medication, disability, repeated hospitalisation and return to independent living 
might be.16 Health-related quality of life may in fact be more improved in older patient 
groups after coronary revascularisation.24 For this, the use of measures such as frailty, 
perhaps in an easy-to-measure guise25 for the post-ACS patient, may guide the clinician better 
as to the appropriateness of more intensive care in the older patient following presentation 
with ACS; they may represent more relevant prognostic indicators in the older patient 
following ACS26 when also taking into consideration that the relative potency of more 
widely-used prognostic measures such as troponin has been reported to attenuate with 
increased age.27 
Strengths and Limitations 
Our data span five years and accrues large numbers of patients across all age groups that are 
representative of a country’s clinical practice. Unlike in clinical trials, the representation of 
the oldest people (aged 85 and over) in our study is a major strength of the observational 
study design. We appreciate however the selection bias that may  have operated in our study, 
and in such a registry cohort design it is impossible to eliminate this bias that occurs on 
allocation of different treatments, care pathways that are relevant to the clinicians' perceived 
prognosis of the patient. However, seeing that the association between lack of cardiologist 
care and worse survival was attenuated markedly by receipt of guideline-supported secondary 
prevention, our study design of real-world clinical practice is important in demonstrating the 
appropriate selection 'triage' of patients into pathways that are of relevance to improve their 
prognosis. The fact that we show that even with specialist cardiologist care preventing death 
in older people is hard to do is of clear clinical relevance, and a finding that would be 
difficult to replicate in a clinical trial design, where it would be unethical to randomise an 
older patient to non-receipt of secondary prevention or specialist cardiologist care. Hence, our 
study design is appropriate to examine the receipt-of-care questions we pose of it. 
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Co-morbidity data were limited (e.g. no data on cancer, dementia etc) and were defined by 
past medical history and not by laboratory data or other objective parameters; thus we were 
unable to explore in greater detail reasons underlying the differences in receipt of care and on 
survival; there may exist unmeasured confounding particularly since cardiologists were more 
likely to care for younger patients with fewer comorbidities, and there could have been 
ascertainment bias which could confound the results. As a registry data we do not have 
information on whether a procedure or treatment was based on patient preference and this 
should be investigated in future studies to better understand the relationships observed in this 
study. We were unable to conclusively examine whether data in MINAP on cardiologist care 
meant that the patient was the reponsibility of the cardiologist, or whether cardiological input 
was provided whilst the patient remained the reponsibility of a general physican. The 
statistical analyses could not control for dosages of medications, and thus we made the 
assumption that secondary prevention when prescribed was at an optimal dose for that 
patient. 
Though it collects data from all 230 hospitals in England and Wales, missingness remains a 
weakness of registry data. However, previous published imputation analyses on the MINAP 
dataset by the lead author28 have not significantly altered effect sizes and imply that 
missingness in MINAP is at random, whilst work by others has also shown that the level of 
missingness of data in MINAP does not alter regional standardised mortality ratios.29 Data on 
admission cholesterol level/past history of dyslipidaemia and receipt of clopidrogrel at 
discharge were also not usable due to failure to pass validation checks and high levels of 
missingness (over 40% for clopidrogrel).  
Finally, cause-specific mortality is not available within MINAP, and most of studies in this 
field including key ones like the GRACE registry similarly report all-cause death as we have 
done.30-31 Importing cause of death into registries like MINAP remains hard to do.  
Conclusion 
We found that among patients with NSTEMI, older patients are less likely to see a 
cardiologist. Cardiologists are more likely to prescribe secondary prevention medication than 
generalists at all ages but this can be mostly explained away by increased co-morbidity in 
patients who remain under generalist care. Patients treated by cardiologists are less likely to 
die, with co-morbidities and secondary prevention medication explaining only part of this 
mortality difference, though the benefit of specialist care is less as the patient ages. Even with 
specialist cardiologist care, it may be that it is simpler harder to prevent death in older people; 
more research is needed to determine which older patients would clearly benefit from 
cardiologist care to ensure optimal and relevant outcomes. Our data here show that at present, 
generalist care may be wholly appropriate in the older NSTEMI patient with multiple co-
morbidities.  
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Table 1 Patients’ Baseline Characteristics and Co-morbidities by Cardiologist/Generalist Care 
         
Age group <65  65-74  75-84  ≥85  
Care  Cardiologist Generalist Cardiologist Generalist Cardiologist Generalist Cardiologist Generalist 
0BN (%) 20,736 (94.6) 1,167 15,687 (91.9) 1,392 17,729 (84.5) 3,260 8,588 (70.1) 3,657 
1BAge, years 
(mean, SD) 
54.9 (7.4) 55.4 (7.5) 70.1 (2.9) 70.6 (2.8) 80.0 (2.8) 80.5 (2.7) 88.7 (3.1) 89.8 (3.6) 
2BMen, n (%) 15,868 (76.5) 845 (72.4) 10,460 (66.7) 870 (62.5) 10,303 (58.1) 1,638 (50.2) 4,099 (47.7) 1,415 (38.7) 
Cardiovascular risk factors 
17 
 
3BCurrent 
smoker, n 
(%) 
9,260 (44.7) 498 (42.7) 3,251 (20.7) 297 (21.3) 1,830 (10.3) 396 (12.2) 387 (4.5) 180 (4.9) 
4BDiabetes, n 
(%) 
3,907 (18.8) 235 (20.1) 4,470 (28.5) 417 (30.0) 4,814 (27.2) 955 (29.3) 1,718 (20.0) 674 (18.4) 
5BHypertension
, n (%) 
8,981 (43.3) 497 (42.6) 9,018 (57.5) 765 (55.0) 11,044 (62.3) 1,851 (56.7) 5,168 (60.2) 2,003 (54.8) 
Co-morbidities 
Congestive 
cardiac 
failure, n (%) 
459 (2.2) 40 (3.4) 930 (5.9) 126 (9.0) 1,702 (9.6) 471 (14.4) 1,198 (14.0) 600 (16.4) 
Chronic 
kidney 
disease, n (%) 
568 (2.7) 54 (4.6) 930 (5.9) 133 (9.6) 1,722 (9.7) 409 (12.6) 973 (11.3) 449 (12.3) 
Cerebrovascu 860 (4.2) 59 (5.1) 1,552 (9.9) 202 (14.5) 2,248 (12.7) 582 (17.9) 1,227 (14.3) 652 (17.8) 
18 
 
lar disease, n 
(%) 
Peripheral 
vascular 
disease, n (%) 
665 (3.2) 62 (5.3) 1,040 (6.6) 125 (9.0) 1,282 (7.2) 246 (7.6) 479 (5.6) 160 (4.4) 
Chronic 
obstructive 
pulmonary 
disease, n (%) 
2,472 (11.9) 189 (16.2) 2,945 (18.8) 367 (26.4) 3,346 (18.9) 796 (24.4) 1,266 (14.7) 576 (15.8) 
In-patient 
bleeding, n 
(%) 
155 (0.8) 12 (1.0) 213 (1.4) 30 (2.2) 346 (2.0) 92 (2.8) 157 (1.8) 127 (3.5) 
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Table 2 Association of Cardiologist Care with Receipt of Treatments Compared to Generalist Care, by Age Group  
 
 
Age group <65 65-74 75-84 ≥85 
 
 
 
 
6BType of care      
 
 
7BCardiologist 
 
 
20,362 (94.7) 15,378 (91.9) 17,392 (84.5) 8,441 (70.2) 
8BGeneralist   1,139 1,361 3,193 3,587 
Prescribed ACE inhibitor  
9BCardiologist (%) 15,081 (74.1) 11,050 (71.9) 11,850 (68.1) 5,171 (61.3) 
10BGeneralist (%) 760 (66.7) 849 (62.4) 1,822 (57.1) 1,832 (51.1) 
11BCrude OR 1.44 (0.94,2.21) 1.53 (1.26,1.85) 1.61 (1.42,1.82) 1.50 (1.35,1.68) 
12BAge/Sex/ACEi on admission adjusted OR 1.40 (0.91,2.16) 1.53 (1.24,1.90) 1.58 (1.38,1.82) 1.39 (1.23,1.57) 
13BAge/Sex/ACEi on admission/CKD adjusted OR 
 
1.38 (0.89,2.14) 1.49 (1.21,1.83) 1.56 (1.35,1.79) 1.38 (1.21,1.57) 
15BFully adjusted  1.07 (0.90,1.27) 1.36 (1.10,1.67) 1.33 (1.15,1.53) 1.15 (1.04,1.27) 
Prescribed aspirin  
16BCardiologist (%) 
 
 
 
16,860 (82.8) 12,239 (79.6) 
 
13,480 (77.5) 
 
6,582 (78.0) 
17BGeneralist (%) 879 (77.2) 1,011 (74.3) 2,258 (70.7) 2,572 (71.7) 
Crude 1.44 (0.85,2.45) 1.34 (1.07,1.67) 1.43 (1.31,1.54) 1.38 (1.17,1.64) 
 Age/sex adjusted 1.44 (0.85,2.44) 1.33 (1.07,1.67) 1.42 (1.18,1.69) 1.37 (1.15,1.63) 
 Age/sex/bleeding adjusted 1.44 (0.84,2.44) 1.33 (1.06,1.67) 1.40 (1.17,1.68) 1.34 (1.12,1.61) 
Fully adjusted  1.05 (0.77,1.44) 1.08 (0.90,1.29) 1.08 (0.94,1.24) 1.04 (0.92,1.18) 
20 
 
Prescribed b-blockers  
18BCardiologist (%) 14,969 (73.5) 10,294 (66.9) 11,233 (64.6) 5,304 (62.8) 
19BGeneralist (%) 719 (63.1) 752 (55.3) 1,682 (52.7) 1,853 (51.7) 
Crude 1.62 (1.17,2.25) 1.64 (1.36,1.98) 1.65 (1.44,1.89) 1.58 (1.36,1.83) 
Age/sex/b-blocker on admission adjusted 1.57 (1.13,2.18) 1.53 (1.26,1.85) 1.57 (1.37,1.81) 1.43 (1.26,1.63) 
Age/sex/ b-blocker on admission/COPD adjusted 1.53 (1.08,2.15) 1.44 (1.18,1.75) 1.52 (1.32,1.76) 1.43 (1.25,1.63) 
Fully adjusted 1.35 (1.04,1.76) 1.29 (1.15,1.43) 1.28 (1.14,1.44) 1.20 (1.04,1.37) 
Prescribed statin  
20BCardiologist (%) 16,891 (83.0) 12,491 (81.2) 13,847 (79.6) 6,414 (76.0) 
21BGeneralist (%) 883 (77.5) 1,055 (77.5) 2,340 (73.3) 2,348 (65.5) 
22BCrude 1.45 (0.83,2.54) 1.23 (0.93,1.64) 1.38 (1.09,1.75) 1.51 (1.27,1.80) 
23BAge/sex/statin on admission adjusted 1.44 (0.83,2.52) 1.24 (0.93,1.65) 1.37 (1.09,1.73) 1.41 (1.17,1.70) 
24BFully adjusted 1.13 (0.74,1.73) 0.90 (0.71,1.13) 1.00 (0.79,1.27) 1.11 (0.92,1.33) 
 
 
OR: odds ratio (95% CI) for cardiologist vs. generalist care within each age group.  
CRF - chronic renal failure; CKD - chronic kidney disease; COPD - chronic obstructive pulmonary disease 
Fully adjusted - adjusted for sex, diabetes, hypertension and smoking; in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-
hospital bleeding; chronic kidney disease, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and 
congestive cardiac failure; receipt of other secondary prevention (three of statin, aspirin, b-blocker, ACE inhibitor excluding the treatment under 
investigation in the model) at discharge, and receipt of treatment under investigation in that model on admission   
 
Data available for all treatments on arrival except aspirin 
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 Table 3 Effect of Cardiologist Versus Generalist Care on Risk of All-cause Death by Age Group 
Age in years HR (95%CI)1 HR (95%CI)2 HR (95%CI)3 HR (95%CI)4 HR (95%CI)5 HR (95%CI)6 
Adjusted for  Sex Cardiovascular 
risk factors 
Disease severity Co-morbidity Secondary 
prevention 
All 
<65 0.52 (0.45,0.61) 0.52 (0.45,0.61) 0.50 (0.42,0.59) 0.62 (0.49,0.77) 0.56 (0.46,0.68) 0.58 (0.49,0.68) 
65-74 0.47 (0.40,0.57) 0.48 (0.41,0.57) 0.48 (0.40,0.57) 0.54 (0.47,0.61) 0.50 (0.42,0.60) 0.55 (0.48,0.63) 
75-84  0.57 (0.49,0.66) 0.58 (0.50,0.67) 0.56 (0.48,0.64) 0.62 (0.53,0.71) 0.60 (0.51,0.69) 0.63 (0.54,0.72) 
≥85  0.78 (0.72,0.84) 0.78 (0.73,0.84) 0.77 (0.72,0.82) 0.79 (0.73,0.86) 0.87 (0.82,0.91) 0.87 (0.82,0.92) 
Cox regression model hazard ratio, HR (95% CI) for cardiologist versus generalist care 
1 Adjusted for sex 
2 Adjusted for sex, diabetes, hypertension and smoking 
3 Adjusted for sex, in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-hospital bleeding 
4 Adjusted for sex, chronic kidney disease, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and 
congestive cardiac failure  
5 Adjusted for sex, receipt of ACE inhibitor, statin, aspirin, b-blocker  
6 Adjusted for all the above  
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Table S1 Effect of Cardiologist Versus Generalist Care on Risk of All-cause Death Within 30 days and One Year by Age Group 
Age in years HR (95%CI)1 HR (95%CI)2 HR (95%CI)3 HR (95%CI)4 HR (95%CI)5 HR (95%CI)6 
Adjusted for  Sex Cardiovascular 
risk factors 
Disease severity Co-morbidity Secondary 
prevention 
All 
<65        
30 days 0.52 (0.35,0.77) 0.53 (0.36,0.78) 0.47 (0.33,0.66) 0.61 (0.41,0.89) 0.62 (0.38,1.02) 0.60 (0.42,0.85) 
1 year 0.46 (0.37,0.57) 0.46 (0.38,0.57) 0.43 (0.35,0.53) 0.76 (0.70,0.83) 0.50 (0.38,0.65) 0.51 (0.41,0.63) 
65-74       
30 days 0.36 (0.27,0.48) 0.36 (0.27,0.49) 0.37 (0.29,0.49) 0.40 (0.30,0.53) 0.36 (0.27,0.50) 0.44 (0.33,0.58) 
1 year 0.44 (0.37,0.52) 0.45 (0.38,0.52) 0.44 (0.37,0.52) 0.54 (0.42,0.69) 0.46 (0.38,0.56) 0.52 (0.45,0.60) 
75-84        
30 days 0.54 (0.42,0.68) 0.55 (0.43,0.69) 0.50 (0.41,0.62) 0.57 (0.45,0.73) 0.57 (0.49,0.66) 0.58 (0.50,0.66) 
1 year 0.56 (0.48,0.66) 0.57 (0.49,0.67) 0.55 (0.47,0.63) 0.50 (0.44,0.56) 0.59 (0.51,0.70) 0.63 (0.54,0.73) 
≥85        
30 days 0.82 (0.68,1.00) 0.83 (0.69,1.01) 0.80 (0.66,0.98) 0.83 (0.68,1.02) 1.06 (0.97,1.16) 0.99 (0.89,1.11) 
23 
 
1 year 0.77 (0.71,0.84) 0.77 (0.71,0.84) 0.76 (0.70,0.83) 0.79 (0.72,0.86) 0.88 (0.82,0.95) 0.88 (0.80,0.95) 
Cox regression model hazard ratio, HR (95% CI) for cardiologist versus generalist care 
1 Adjusted for sex 
2 Adjusted for sex, diabetes, hypertension and smoking 
3 Adjusted for sex, in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-hospital bleeding 
4 Adjusted for sex, chronic kidney disease, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and 
congestive cardiac failure  
5 Adjusted for sex, receipt of ACE inhibitor, statin, aspirin, b-blocker  
6 Adjusted for all the above  
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